Deal facts
- Buyer
- Novartis AG
- Target
- Tourmaline Bio, Inc.
- Deal value
- USD 1,153,403,296
- Announced
- 8 September 2025
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Novartis AG completes acquisition of Tourmaline Bio, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated as of September 8, 2025 (the “ Merger Agreement ”), by and among Tourmaline Bio, Inc., a Delaware corporation (the “ Company ”), Novartis AG, a company limited by shares ( Aktiengesellschaft ) in
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
GlaxoSmithKline LLC to acquire Nuvalent, Inc.
GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…
- Buyer
- GlaxoSmithKline LLC
- Target
- Nuvalent, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
FONAR, LLC to acquire FONAR Corporation
FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…
- Buyer
- FONAR, LLC
- Target
- FONAR Corporation
- Deal value
- Not disclosed
- Deal type
- going private
Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.
Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…
- Buyer
- Zydus Worldwide DMCC
- Target
- Assertio Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Novartis AG
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive